INOTUZUMAB OZOGAMICIN FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL: EFFICACY AND SAFETY BY PRIOR THERAPY

被引：0

作者：

DeAngelo, D. J. ^{[1
]}

Jabbour, E. J. ^{[2
]}

Stelljes, M. ^{[3
]}

Liedtke, M. ^{[4
]}

Stock, W. ^{[5
]}

Goekbuget, N. ^{[6
]}

Martinelli, G. ^{[7
]}

O'Brien, S. ^{[8
]}

Wang, K. ^{[9
]}

Wang, T. ^{[10
]}

Paccagnella, M. L. ^{[10
]}

Sleight, B. ^{[10
]}

Vandendries, E. ^{[11
]}

Advani, A. S. ^{[12
]}

Kantarjian, H. M. ^{[2
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Klinikum mUNSTER, Munster, Germany

[4] Stanford Canc Ctr, Stanford, CA USA

[5] Univ Chicago Med, Chicago, IL USA

[6] Univ Hosp Frankfurt, Frankfurt, Germany

[7] Univ Bologna, Bologna, Italy

[8] Univ Calif Irvine, Orange, CA 92668 USA

[9] Pfizer Inc, Pearl River, NY USA

[10] Pfizer Inc, Groton, CT 06340 USA

[11] Pfizer Inc, Cambridge, MA USA

[12] Cleveland Clin Main Campus, Cleveland, OH USA

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S499

引用

页码：184 / 184

页数：1

共 50 条

[31] The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study
Ozcan, Muhit
Cassaday, Ryan D.
Singh, Pawan
Zarzycka, Ewa
Zhang, Xin
Negre, Eric
Vandendries, Erik
Altuntas, Fevzi
BLOOD, 2021, 138
[32] Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)
Stelljes, Matthias
Su, Yun
Fahrbach, Kyle
Vandendries, Erik
Page, Veronique
Onyekwere, Uchenna
Wang, Yunyang
Cappelleri, Joseph C.
Proskorovsky, Irina
BLOOD, 2017, 130
[33] WEEKLY INOTUZUMAB OZOGAMICIN (INO) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
DeAngelo, D. J.
Stock, W.
Shustov, A. R.
Ananthakrishnan, R.
Luu, K.
Boni, J.
Volkert, A.
Vandendries, E.
Advani, A. S.
HAEMATOLOGICA, 2013, 98 : 463 - 464
[34] LONG-TERM SAFETY OF INOTUZUMAB OZOGAMICINE IN PATIENTS WITH RESISTANT ACUTE LINFOBLASTIC LEUKEMIA OR IN COLLAPSE INCLUDED IN CLINICAL SENSING PHASE 3 INO-VATE
Ribera Santasusana, J. M.
De Angelo, D. J.
Cassaday, R.
Martinelli, G.
Stock, W.
Stelljes, M.
Goekbuget, N.
Advani, A.
O'Brien, S.
Liedtke, M.
Merchant, A.
Wang, T.
Vandendries, E.
Marks, D., I
Jabbour, E.
Kantarjian, H.
HAEMATOLOGICA, 2018, 103 : 26 - 26
[35] Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
Pennesi, Edoardo
Michels, Naomi
Brivio, Erica
van der Velden, Vincent H. J.
Jiang, Yilin
Thano, Adriana
Ammerlaan, Anneke J. C.
Boer, Judith M.
Beverloo, H. Berna
Sleight, Barbara
Chen, Ying
Vormoor-Buerger, Britta
Rives, Susana
Bielorai, Bella
Roessig, Claudia
Petit, Arnaud
Rizzari, Carmelo
Engstler, Gernot
Stary, Jan
Bautista Sirvent, Francisco J.
Chen-Santel, Christiane
Bruno, Benedicte
Bertrand, Yves
Rialland, Fanny
Plat, Genevieve
Reinhardt, Dirk
Vinti, Luciana
Von Stackelberg, Arend
Locatelli, Franco
Zwaan, Christian M.
LEUKEMIA, 2022, 36 (06) : 1516 - 1524
[36] Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
Edoardo Pennesi
Naomi Michels
Erica Brivio
Vincent H. J. van der Velden
Yilin Jiang
Adriana Thano
Anneke J. C. Ammerlaan
Judith M. Boer
H. Berna Beverloo
Barbara Sleight
Ying Chen
Britta Vormoor-Bürger
Susana Rives
Bella Bielorai
Claudia Rössig
Arnaud Petit
Carmelo Rizzari
Gernot Engstler
Jan Starý
Francisco J. Bautista Sirvent
Christiane Chen-Santel
Benedicte Bruno
Yves Bertrand
Fanny Rialland
Geneviève Plat
Dirk Reinhardt
Luciana Vinti
Arend Von Stackelberg
Franco Locatelli
Christian M. Zwaan
Leukemia, 2022, 36 : 1516 - 1524
[37] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Ueda, Tomoaki
Fukushima, Kentaro
Kusakabe, Shinsuke
Yoshida, Koki
Suga, Makiko
Nakai, Ritsuko
Koike, Midori
Hino, Akihisa
Akuta, Keigo
Toda, Jun
Nagate, Yasuhiro
Doi, Yukiko
Fujita, Jiro
Yokota, Takafumi
Hosen, Naoki
LEUKEMIA RESEARCH REPORTS, 2022, 17
[38] EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN (INO) VS STANDARD OF CARE (SOC) IN SALVAGE 1 OR 2 PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): AN ONGOING GLOBAL PHASE 3 STUDY
DeAngelo, D. J.
Stelljes, M.
Martinelli, G.
Kantarjian, H.
Liedtke, M.
Stock, W.
Goekbuget, N.
Wang, K.
Pacagnella, L.
Sleight, B.
Vandendries, E.
Advani, A. S.
HAEMATOLOGICA, 2015, 100 : 337 - 337
[39] Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial
Pennesi, Edoardo
Brivio, Erica
Pelletier, Kathleen B.
Chen, Ying
Huitema, Alwin D. R.
Jiang, Yilin
Ammerlaan, Anneke C. J.
Sleight, Barbara
Locatelli, Franco
Van der Sluis, Inge M.
Rossig, Claudia
Chen-Santel, Christiane
Bielorai, Bella
Petit, Arnaud
Stary, Jan
Sramkova, Lucie
de Heredia Rubio, Cristina Diaz
Rives, Susana
O'Marcaigh, Aengus
Rizzari, Carmelo
Engstler, Gernot
Nysom, Karsten
Rubio-San-Simon, Alba
Sirvent, Francisco J. Bautista
Bruno, Benedicte
Bertrand, Yives
Brethon, Benoit
Rialland, Fanny
Plat, Genevieve
Dirksen, Uta
Garrett, May
Zwaan, Christian M.
BLOOD, 2022, 140 : 8845 - 8847
[40] INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia
Papayannidis, Cristina
Petracci, Elisabetta
Zappasodi, Patrizia
Fracchiolla, Nicola
Ciceri, Fabio
Sartor, Chiara
Roncoroni, Elisa
Di Raimondo, Francesco
Mattei, Daniele
Giannini, Maria Benedetta
Lanza, Francesco
Gottardi, Michele
Del Principe, Maria Ilaria
Borlenghi, Erika
Fumagalli, Monica
Vallisa, Daniele
Sica, Simona
Di Renzo, Nicola
Fabbiano, Francesco
Todisco, Elisabetta
de Fabritiis, Paolo
Luppi, Mario
Passamonti, Francesco
Corradini, Paolo
Petruzziello, Fara
Pane, Fabrizio
Ferrara, Felicetto
Mambelli, Greta
Volpi, Roberta
Frabetti, Federica
Zingaretti, Chiara
Marconi, Giovanni
Martinelli, Giovanni
CANCER, 2025, 131 (07)

← 1 2 3 4 5 →